DealsJun 11, 2026, 04:22 PM
AIM ImmunoTech Raises $2.65M via Stock and Warrant Offering
AI Summary
AIM ImmunoTech Inc. has entered into definitive agreements for a registered direct offering and a concurrent private placement, aiming to raise approximately $2.65 million in gross proceeds. The offerings include the sale of common stock, pre-funded warrants, and Class J warrants. Ladenburg Thalmann & Co. Inc. is serving as the exclusive placement agent. The net proceeds are intended for manufacturing clinical drug supply, current and planned clinical trial activities, and working capital.
Key Highlights
- AIM ImmunoTech to issue 2,554,119 shares of common stock at $0.5189 per share in a registered direct offering.
- Concurrent private placement includes 771,503 unregistered shares, pre-funded warrants for up to 1,782,616 shares, and Class J warrants for up to 10,216,476 shares.
- Gross proceeds from the registered offering are expected to be approximately $1.3 million.
- Potential additional gross proceeds of approximately $5.3 million if all warrants are exercised for cash.
- Ladenburg Thalmann & Co. Inc. acting as exclusive placement agent, receiving an 8.0% cash fee and 0.75% management fee.
- Placement agent to receive warrants for 306,494 shares of common stock (6.0% of offering shares).
Price Impact
More from AIM